ScreenerHero

DYNDyne Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · dyne-tx.com
26.10USD-2.54%Mkt Cap: 4.87B $P/E: —

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.87B $
Enterprise Value4.19B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-446.21M $
Revenue/Share—
Last Price26.10 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees289
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.78
PEG—
EV/EBITDA-7.83
EV/Revenue—
P/S—
P/B6.13
EPS (TTM)-3.16
EPS (Forward)-3.34
52W Range
11.6492% of range27.30
52W High27.30 USD
52W Low11.64 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.90%
ROA-37.59%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-403.21M $
CapEx (TTM)20.71M $
FCF Margin—
FCF Yield-6.51%
Net Debt-665.13M $
Net Debt/EBITDA1.24
Balance Sheet
Debt/Equity0.17
Current Ratio12.02
Quick Ratio11.52
Book Value/Sh4.238 USD
Cash/Share4.811 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.40 USD
Upside (mean)+51.0%
Target Range17.00 USD – 50.00 USD
$17.00+51.0% to mean$50.00
# Analysts15
Ownership
Shares Out.186.75M
Float186.27M
Insiders0.24%
Institutions103.74%
Short Interest
Short Ratio8.3d
Short % Float15.05%
Short % Out.11.76%
Shares Short21.97M
Short (prev mo.)22.30M
Technical
SMA 5023.38 (+11.7%)
SMA 20019.60 (+33.1%)
Beta1.08
S&P 52W Chg18.16%
Avg Vol (30d)2.24M
Avg Vol (10d)1.84M
Technical Indicators
RSI (14)58.3
MACD0.8809
MACD Signal1.0263
MACD Hist.-0.1453
BB Upper27.21 USD
BB Middle25.77 USD
BB Lower24.34 USD
BB Width11.12%
ATR (14)1.133 USD
Vol Ratio (20d)0.46x